FDA Expands Imiglucerase Approval to Treat Type 3 Gaucher Disease

here’s a summary ​of the provided list⁤ of references:

this is a list⁣ of resources related to⁣ Gaucher disease and the ​treatment Cerezyme ​(imiglucerase). The references ‍include:

* ⁣ Sanofi’s summary ⁤ of a clinical⁣ study (RC-91-0110) related to​ Cerezyme.
*⁤ A‍ clinical update on Cerezyme ⁢ from ⁤Optum, detailing an expanded ‍indication.
* ⁣ Information ⁣about the ⁣ International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry (ClinicalTrials.gov identifier: NCT00358943).

all resources were accessed around⁣ January 26, 2026, with the ICGG registry being updated ‍on January‌ 6, ⁢2026. The links provided‌ are to⁣ PDF documents and a ClinicalTrials.gov entry.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.